Related Experiment Video

Updated: Jun 23, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Novel HSD17B13 Inhibitors for Treating Liver Diseases

Ram W Sabnis1

  • 1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

ACS Medicinal Chemistry Letters
|June 19, 2024
PubMed
Abstract

None:

Provided herein are novel HSD17B13 inhibitors, pharmaceutical compositions, use of such compounds in treating liver diseases, and processes for preparing such compounds.

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.3K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K

Related Experiment Videos

Last Updated: Jun 23, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.3K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

646
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
646
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146

Articles linked to this work by shared authors, journal, and citation graph.

Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.

ACS medicinal chemistry letters·2026

Novel Compounds as SARS-CoV-2-Related 3C-Like Protease Inhibitors for Treating Coronavirus Infections.

ACS medicinal chemistry letters·2026

Novel Compounds as Orexin 2 Receptor Agonists for Treating Narcolepsy.

ACS medicinal chemistry letters·2026

Novel Heterocyclic Compounds for Treating HIV Infection.

ACS medicinal chemistry letters·2026

Novel N‑Oxide Derivatives for Treating HIV Infection or AIDS or AIDS Related Complex.

ACS medicinal chemistry letters·2026

Novel Benzofuran Derivatives as SARM1 Inhibitors for Treating Axonal Degeneration.

ACS medicinal chemistry letters·2026

Understanding the Photodynamic Behavior of Red Emitting Re(I)dipyrrinates in Triple-Negative Breast Cancer Cells.

ACS medicinal chemistry letters·2026

Novel 1H-Indole-3-carboxamide Derivatives as CDK4 Inhibitors for Treating Cancer.

ACS medicinal chemistry letters·2026

Targeted Degradation of CDK2: A New Strategy for Overcoming Cyclin E‑Driven Cancers.

ACS medicinal chemistry letters·2026

Synthetic Diastereomers of the Fungal Cycloheptapeptide Paraisariamide A Retain Ternatin-Like Biological Activity.

ACS medicinal chemistry letters·2026

Novel Compounds as SARS-CoV-2-Related 3C-Like Protease Inhibitors for Treating Coronavirus Infections.

ACS medicinal chemistry letters·2026

Polyamines are i-motif disruptors.

Molecular therapy. Nucleic acids·2026

Peptidomic evidence for pH-stat flavourzyme-mediated debittering of Alcalase-derived rice protein hydrolysates.

Current research in food science·2026

Peptide tiling across viral proteomes identifies modular regulators of stress-induced cell death.

bioRxiv : the preprint server for biology·2026

PANCS-Inhibitors: A rapid method to directly select for protein-protein interaction inhibitors.

bioRxiv : the preprint server for biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us